Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.
Increased understanding of pediatric acute lymphoblastic leukemia (ALL) pathobiology has led to dramatic improvements in patient survival. However, there is still a need to develop targeted therapies to enable reduced chemotherapy intensity and to treat relapsed patients. The interleukin-7 receptor α (IL-7Rα) signaling pathways are prime therapeutic targets because these pathways harbor genetic aberrations in both T-cell ALL and B-cell precursor ALL. Therapeutic targeting of the IL-7Rα signaling pathways may lead to improved outcomes in a subset of patients.
Cytokines and Immunity Section, Cancer and Inflammation Program, National Cancer Institute, National Institutes of Health, Frederick, MD; Comparative Biomedical Scientist Training Program, National Institutes of Health, Bethesda, MD; Department of Veterinary Medicine, University of Maryland, College Park, MD; and.
Sarah D
SD
Cramer
Leukemia Biology Section, Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Peter D
PD
Aplan
Cytokines and Immunity Section, Cancer and Inflammation Program, National Cancer Institute, National Institutes of Health, Frederick, MD;
Scott K
SK
Durum
D006801:Humans; D015851:Interleukin-7 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*
C508605:IL7 protein, human; D015851:Interleukin-7; D009363:Neoplasm Proteins